Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Eli Lilly and Company (NYSE: LLY) today announced it will present 13 abstracts on two late-stage investigational medicines from its diabetes pipeline at the 73rd American Diabetes Association Scientific Sessions? in Chicago June 21-25.
Lilly will share information including, but not limited to, efficacy and safety data for investigational compounds from two different classes of diabetes medicines. This research, which demonstrates the company's commitment to the everyday needs of people with diabetes, includes:
Dulaglutide: The company will disclose efficacy and safety results, as well as health outcomes findings, from three Phase III clinical trials for its investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, dulaglutide.
Novel Basal Insulin: Additional analyses of Phase II data for patients with type 1 and type 2 diabetes will be presented for LY2605541, an investigational novel basal insulin analog.
http://www.sacbee.com/2013/06/11/5487662/lilly-to-highlight-late-stage.html
Lilly will share information including, but not limited to, efficacy and safety data for investigational compounds from two different classes of diabetes medicines. This research, which demonstrates the company's commitment to the everyday needs of people with diabetes, includes:
Dulaglutide: The company will disclose efficacy and safety results, as well as health outcomes findings, from three Phase III clinical trials for its investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, dulaglutide.
Novel Basal Insulin: Additional analyses of Phase II data for patients with type 1 and type 2 diabetes will be presented for LY2605541, an investigational novel basal insulin analog.
http://www.sacbee.com/2013/06/11/5487662/lilly-to-highlight-late-stage.html